July 15, 2025 4:29pm

With “Uncle algo and his electronic trading dwarfs” in the house

Econs are also flashing their “six,” adding uncertainty into the week/month’s equation ahead of the monthly inflation reports as tariffs impact pricing across the US economy.

News: MiMedx (MDXG -$0.47 or -6.91 to $6.33) Shares fell after CMS Proposal <Read in The Bottom Line>

I say what others won’t, so you can do what others can’t!

I also try to answer as many whys, as I can … while providing the metrics to validate my thesis

Never leave an investor uninformed! 

 

My perspective is retail investors should roll-the-dice with econ readings until earnings season kicks-in and momentum wains in the cell and gene therapy sector. NO all ins as historically “our” universe slips and slides as the “season’ resumes; so, hang-in with those with solid partners, lengthened runways and solid cash positions leveraged by solid/stable management teams!

 

Tuesday’s RegMed Investors’ (RMi) pre-open: want to play CLUE … https://www.regmedinvestors.com/articles/13997

Monday night’s RegMed Investors (RMi) Closing Bell: key words today, negotiating down … https://www.regmedinvestors.com/articles/13996

RegMed Investors (RMi) Research Note: Harvard Apparatus GT (OTCQB: HRGN): PONZI Scheme at its best or was convicted Bernie Madoff also resurrected … https://www.regmedinvestors.com/articles/13812

 

Tuesday: The Dow closed DOWN -436.36 points or -0.98%, the S&P closed DOWN -24.80 points or -0.40% while the Nasdaq closed UP +37.47 points or +0.18%

  • Theme of the session, worries over econs, inflation and bank earnings dragged indexes lower

Henry’omics: We need to more than consider the economic environment - rising rates and inflation to comprehend the micro re “our” universe of cell and gene therapy

  • June inflation data released represented an increase from May inflation levels; while it’s a relief to see CPI in-line with expectations, it still showed that inflation was hotter in June than it was in May advancing 2.7% year over year and 0.3% month over month. So-called core CPI, which excludes food and energy prices, grew by 0.2% for the month.
  • The New York Fed’s Empire State Manufacturing index jumped to 5.5, a nearly 22-point improvement over the prior month and much better than the -9.5 forecast. The gauge measures the percentage difference between companies reporting expansion against contraction. Within the index, new orders surged 16.2 points to positive level, while shipments soared 18.7 points to 11.5 and inventories climbed 14.7 points to 15.6. The prices paid index accelerated but the prices received index nudged lower while the employment index also improved, rising to 9.2, up 4.5 points from June.

Tuesday’s advance/decline line opened negative with 2 incliners, 30 decliners and 3 flats ending with a negative close of 3 incliners, 29 decliners and 3 flats         

Metrics:  Tuesday, the IBB was down -2.84%, the XBI was down -2.36% while the VIX was up +0.12 points or +0.81% at 17.34

 

Q3 – 7/25 – 1 market holiday, 7 positive and 3 negative closes

Q2/25:

  • June – 1 market holiday, 1 neutral, 9 negative and 11 positive closes
  • May – 1 market holiday, 10 negative and 11 positive closes
  • April – 11 positive and 10 negative closes

 

Tuesday Closing UP (3 of 3) +$ after Monday’s

  • Harvard Apparatus RT (OTCQB+$0.09 after Monday’s -$0.015)
  • Compass Therapeutics (CMPX +$0.06 after Monday’s +$0.22),
  • Sage Therapeutics (SAGE +$0.02 after Monday’s -$0.12),

Flat (3)

  • bluebird bio (BLUE) P/E acquired
  • Brainstorm Cell Therapeutics (BCLI)
  • Homology Medicine (FIXX)

Tuesday’s Closing DOWN (10 of 29): 

  • Alnylam Pharmaceuticals (ALNY -$4.63 after Monday’s +$0.81),
  • CRISPR Therapeutics (CRSP -$3.69 after Monday’s -$0.38),
  • Vericel (VCEL -$2.72 after Monday’s -$0.11),
  • Ultragenyx Pharmaceuticals (RARE -$2.03 after Monday’s -$0.28),
  • Beam Therapeutics (BEAM -$1.59),
  • Moderna (MRNA -$1.29 after Monday’s -$0.77),
  • BioLife Solutions (BLFS -$1.24),
  • Lenz Therapeutics (LENZ -$0.98 after Monday’s -$0.96),
  • Agenus (AGEN -$0.61 after Monday’s -$0.23),
  • uniQure NV (QURE -$0.59 after Monday’s +$0.15),

 

The BOTTOM LINE:  The Dow and the S&P ebbed as the Nasdaq flowed as econs aided by “uncle algo and his electronic trading dwarfs” “crunched” the upside

  • Volume was higher on the Nasdaq and the NYSE compared with the same time on Monday.
  • The small-cap Russell 2000 fell 1.3%. In the bond market, the yield on the benchmark 10-year Treasury note gained to 4.49%.

Some not so bad news: MiMedx (MDXG -$0.47 or -6.91 to $6.33) Shares fell after CMS Proposal to cut spending on Skin Substitute Products

  • The proposed rule calls for a move away from the ASP methodology in favor of a fixed price per square centimeter of $125.38 for all skin substitutes. While many may take issue with the proposed price, reform in this category is long overdue,” stated Joseph H. Capper, MIMEDX Chief Executive Officer.
  • Mr. Capper continued, “The skin substitute market has experienced a proliferation of unsavory business practices over the last several years, as referenced in several recently announced enforcement actions. Under the current reimbursement methodology, the 2024 Medicare spend for skin substitutes in the private office and associated care settings had ballooned to nearly $10 billion, up from approximately $1.5 billion in 2022.
  • MIMEDX is well-positioned to excel in an environment in which product capabilities, supported by robust clinical evidence, determine selection and usage.

Cell and gene therapy sector equities popped on Monday followed by a dive on Tuesday …

After popping on Friday, Thursday and Wednesday continued the upside after Tuesday positive close and diving on Monday ….

  • After last week popping multiple positive closes (Thursday, Wednesday, Tuesday and Monday) in this new month, July and Q.

As I also wrote, the “June Swoon” is over … however, July will be no better or worse than any other month. Although, I consider the so-called summer rally after the peripatetic or wandering.”

  • There are always some big ifs, especially given some of the headlines that could emanate after a past few months of news flatulence.

Last session of June as July evolves ‘25: understand the “flow” …

  • 7/15 – Tuesday closed negative with 3 positive, 29 negative and 3 flats
  • 7/14 - Monday closed positive with 20 positive, 11 negative and 4 flats
  • 7/11 - Friday closed negative with 5 positive, 28 negative and 2 flats
  • 7/10 - Thursday closed positive with 19 positive, 14 negative and 2 flats
  • 7/9 – Wednesday closed positive with 28 positive, 5 negative and 2 flats
  • 7/8 - Tuesday closed positive with 22 positive, 10 negative and 3 flats
  • 7/7 – Monday closed negative with 6 positive, 27 negative and 2 flats
  • 7/4 – Friday market holiday
  • 7/3 – Thursday closed positive with 23 positive, 6 negative and 6 flats
  • 7/2 - Wednesday closed positive with 24 positive, 7 negative and 4 flats
  • 7/1 – Tuesday closed positive with 21 positive, 11 negative and 3 flats
  • 6/30 - Monday closed positive with 20 positive, 11 negative and 4 flats

 

“I hate to be so negative or contrarian but, this is a NO spin zone and truth is its product; I can always be WRONG but, I am mostly EARLY!”

  • If I have learned one thing as a former research analyst in a venture and public fund, operating executive, x-FBI, x-military officer and an adjunct (MBA) business school professor now a journalist; my life and your portfolio are largely tied to knowledge of price movements and questioning pricing targets and more.
  • I was once told by a “very” prominent figure early in my career, “write it right, keep it tight without hype and never lose the stride to guide the reader” – they were pretty simple instructions to follow!

 

Why do I keep repeating, so investors can make the connection …

The top three (3) performing in the session:   

  • Tuesday: Harvard Apparatus RT (OTCQB: HRGN), Compass Therapeutics (CMPX) and Brainstorm Cell Therapeutics (BCLI)
  • Monday: Ionis Pharmaceuticals (IONS), Alnylam Pharmaceuticals (ALNY) and Cellectis SA (CLLS)
  • Friday: Lenz Therapeutics (LENZ), Agenus (AGEN) and Mesoblast (MESO)

The worst three (3) in the session: 

  • Tuesday: Alnylam Pharmaceuticals (ALNY), CRISPR Therapeutics (CRSP) and Vericel (VCEL)
  • Monday: Lenz Therapeutics (LENZ), Moderna (MRNA)and CRISPR Therapeutics (CRSP)
  • Friday: Alnylam Pharmaceuticals (ALNY), CRISPR Therapeutics (CRSP) and Ultragenyx Pharmaceuticals (RARE)

Welcome to my world of defining the “grey’ in our universe!

  • Right up front, “I also hate to be so negative or contrarian but, this is a NO spin zone and facts are its product; I can always be WRONG but … I am mostly EARLY!”

 

Opinions expressed are those of the author and are subject to change, and not intended to be a forecast of future events, a guarantee of future results, nor investment advice. Whether information or intelligence is good, bad, or somewhere in between; I put into context what is relevant and useful for investors.  All investments are subject to risks. Investors should consider investment objectives.

Henry McCusker, the editor, and publisher of RegMed Investors does not hold or have positions in securities referred to in this publication. Regulation Analyst Certification (Reg AC): The research analyst primarily responsible for the content of this report certifies the following under Reg AC: I hereby certify that all views expressed in this report accurately reflect my personal views about the subject company or companies and it’s or their securities.

I also certify that no part of my compensation was, is or will be, directly or indirectly, related to the specific recommendations or views expressed in this report.